Breaks Categories: Stock Spotlights

FridayFeb 18, 2022 1:42 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO Hails Potential of Promising Psychedelic Medicines

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18%…

Continue Reading

TuesdayFeb 15, 2022 3:20 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Distinctive with Phased Approach to Novel Therapeutics Development

Mydecine (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’s goals for the new year. Of note was Mydecine’s phased approach, which entails understanding the imperfections of initial formulations and then improving aspects such as the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc., in order to make them more effective. This approach has set the company apart from its peers. A…

Continue Reading

MondayFeb 14, 2022 1:52 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with a network of world-class partners and internationally recognized scientists as it focuses on creating safe and effective therapeutics for patients to address a multitude of mental health issues. “The company is working on turning its Psychedelics to Therapeutics(TM) vision into reality by engineering drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders,” reads a recent article, which contains excerpts…

Continue Reading

WednesdayFeb 09, 2022 2:26 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Bringing Science-Backed Health Benefits to All, Reframing Psychedelic Conversation

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has sought to capitalize on the ongoing transformation within the mental health sector. The company is positioning itself as the United States’ leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. This comes as Representative Earl Blumenauer recently circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit terminally ill patients to use psilocybin as part of their treatment without fear of being federally prosecuted. Although the DEA has remained steadfast in…

Continue Reading

FridayFeb 04, 2022 1:58 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to success. The company was awarded a notice of allowance by the U.S. Patent and Trademark Office for its CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for its co-funded investigator-initiated phase 2 clinical trial. Cybin also confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding its lead candidate CYB003 for the treatment of major…

Continue Reading

MondayJan 31, 2022 3:31 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) Bringing Safer, More Effective Nicotine Dependence Treatment to Market

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in an excellent position to tap into the opportunities offered by the smoking cessation market. In early 2021, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing sector rife with opportunity. “Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (‘JHU’) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment… In 2022, Johnson…

Continue Reading

MondayJan 24, 2022 12:08 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Access of New Medicines, Treatment for Mental Health Conditions

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently announced its wholly owned ketamine infusion clinic chain, Ketamine Wellness Centers LLC (“KWC”), will open two new clinics in Salt Lake City, Utah, and Reno, Nevada, by February 2022. KWC, at that time, had cumulatively delivered over 60,000 treatments across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. A recent article reads, “Delic will open 13 ketamine infusion clinics across the country over the next 18 months, adding to the company’s existing portfolio, which comprises of 12 KWC clinics as well as two clinics operated by subsidiary…

Continue Reading

WednesdayJan 19, 2022 1:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”). The notice was regarding Cybin’s patent application connected to its investigational deuterated psychedelic tryptamine compound, CYB004, for the potential treatment of anxiety disorders. “The receipt of this notice of allowance from the USPTO represents an important milestone in expanding our intellectual property portfolio progressing psychedelics to therapeutics for the countless patients in need, and strongly demonstrates the company’s dedication to the discovery and development of differentiated psychedelic-based…

Continue Reading

FridayJan 07, 2022 11:26 am

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Presence, Access Within Psychedelic Wellness Space

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, recently sought to expand its presence within psychedelic wellness, entering into a merger agreement with Ketamine Wellness Centers LLC (“KWC”). KWC boasts the nation’s largest chain of psychedelic wellness clinics. A recent article reads, “Under the terms of the deal, Delic agreed to acquire KWC’s chain of 10 ketamine infusion clinics, operating across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington, and merge them with Delic’s existing two ketamine clinics operating under Ketamine Infusions Centers (‘KIC’). Delic now expects to open 15 additional clinics across the country over…

Continue Reading

TuesdayJan 04, 2022 2:01 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Support Low-Cost/No-Cost Psychedelic Clinic for Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones to revolutionize mental health care. Among these, the company recently secured a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital. The hospital is part of Northwell Health, the largest health care system in New York State, and serves marginalized communities on the Upper East Side of Manhattan. Lenox Hill is working to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. A recent article quotes Cybin Chief Clinical Officer Dr. Alex…

Continue Reading